All
Resistance to BRAF inhibitors may be overcome with malaria drug
February 24th 2014Though half of melanoma patients with the BRAF mutation respond positively to treatment with BRAF inhibitors, most develop resistance to the drugs and experience disease progression. A new study suggests a drug used to treat malaria may help to block the pathway that causes this BRAF inhibitor resistance.
Congress agrees to repeal sustainable growth rate formula
February 11th 2014Members of Congress have reached an agreement that would repeal the sustainable growth rate formula, which is used to determine Medicare reimbursement rates for physicians. The agreement allows for guaranteed annual reimbursement increases of 0.5 percent over the next five years for Medicare providers.
PSOLAR results show no patterns of cardiovascular events
February 4th 2014Recent reports on results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study show there are no distinct patterns of major adverse cardiovascular events (MACE), and there are limited rates of malignancy, overall.
Antibiotic dialogue needs to continue
February 1st 2014I thoroughly enjoyed the lead article about “antimicrobial stewardship” in the October edition of Dermatology Times (“Antimicrobial stewardship: How dermatologists can be part of the solution, Vol. 34, No. 10). It succinctly and effectively detailed that for healthcare providers in general and dermatologists in specific, it is our duty to utilize antimicrobials appropriately.
Derms slow to embrace subantimicrobial dose concept
February 1st 2014Dermatologists might slash the development of resistance to antibiotics by embracing lower, subantimicrobial doses for acne cases that require only anti-inflammatory activity, experts say. However, they add, getting the majority of dermatologists to accept this message likely will prove challenging.
ATX-101 studies yield favorable findings for reducing submental fat
February 1st 2014Top-line results from North American phase 3 clinical trials show that a series of injections with ATX-101 is safe, well-tolerated, and results in clinically meaningful and statistically significant reductions in submental fat or “double chin.”
Early treatment of severe psoriasis may curb comorbidities
February 1st 2014There is a suggestion that early treatment of severe psoriasis will decrease the risk of cardiovascular comorbidities that have been associated with severe psoriasis such as stroke and heart attack, according to a clinical professor dermatology at the State University of New York Buffalo School of Medicine.
Rising skin cancer rate spurs drive for new therapies
February 1st 2014The commercialization of ingenol mebutate (Picato, LEO Pharma) a medication that is currently approved in the United States and many other countries for the treatment of actinic keratosis, is an example of how enthusiasm and commitment can drive innovation, a LEO Pharma general manager says.
Drug-resistant disease re-emerge, gain strength
February 1st 2014Key concerns regarding infectious diseases with cutaneous manifestations include the expanding reach of infections formerly thought rare and exotic, experts say. Meanwhile, they add, some infections rarely seen stateside in recent years are resurging.
PODCAST: A plethora of aesthetic products
February 1st 2014Cosmetic concerns are important to many of our patients. Among the difficulties faced by consumers is the blitz of advertising of new and presumably revolutionary products that can rejuvenate and preserve the youthful appearance of the skin. Many products make what sound like medical claims about the efficacy of these agents. Norman Levine, M.D., asked Zoe Draelos, M.D., the foremost authority on this subject, to discuss these issues with us.